Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier takes Proactive's Stephen Gunnion through the company’s annual results and latest business update. He highlighted progress across Scancell’s clinical pipeline, particularly the SCOPE study in melanoma. L’Huillier said the trial has answered four critical questions, including product selection, target patient population, administration, and dosing schedule. The company has chosen its iSCIB1+ candidate for further development, after observing “meaningful clinical benefit comes from administering our drug on top of standard of care.” He noted that the therapy is showing strong results in patients with specific HLA haplotypes, with the ability to use a screening tool to identify responders for future trials. On efficacy, L’Huillier explained: “In our combined cohort, in the target population where we've got 72 patients, we're seeing a progression-free survival of 69% at 22 months. And if you compare that to the historic standard of care, it's 11.5 months.” The CEO also discussed the Modi-1 programme in phase 2 for head and neck cancer and renal cell carcinoma, and progress on antiglycan antibodies, which are being advanced under a new subsidiary. Looking ahead, Scancell is preparing for regulatory discussions with the FDA, EMA and MHRA, while also engaging potential partners and investors. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Scancell #CancerResearch #Biotech #Melanoma #ClinicalTrials #Immunotherapy #Pharma #Biotechnology #CancerTreatment #Oncology